The Latest Breaking News from Cathie Wood

Tesla's board chair says Musk's pay is a matter of "fairness" after he sped past the company's targets. Some investors are less convinced.

This is “hubris,” said the former audit chairman and VC.

This article delves into three biotech stocks held in Cathie Wood's ARKK ETF that analysts expect to double in value. Investors looking to add exposure to promising biotech opportunities, with a preference for Wood's disruptive approach to investing, may find these stocks particularly compelling.

Her flagship Ark Innovation ETF has slumped 20% year to date.

Ahead of an inflation report due Friday before the opening bell, the Nasdaq composite slumped 0.7%.

Why does Cathie Wood think investors' fear about stocks is at "Great Depression" levels? Because it is for her portfolio.

The S&P 500 information tech stock index has climbed 17% year to date.

Cathie Wood splurged millions in biotech this year on strong clinical progress, AI adoption, sales growth, wider outreach, and steady product pipelines.

These two Cathie Wood stocks, which have earned a vote of confidence from Bank of America, are sailing past the broader market this year.

Her flagship ETF has slumped 16% year to date.

Cathie Wood's ARK Innovation is having a terrible year vs. the S&P 500 — but it still has one thing going for it. At least it's not the worst.